Avestar Capital LLC Has $760,000 Position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Avestar Capital LLC grew its holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 7.7% in the third quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 723 shares of the biopharmaceutical company’s stock after acquiring an additional 52 shares during the quarter. Avestar Capital LLC’s holdings in Regeneron Pharmaceuticals were worth $760,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also modified their holdings of REGN. International Assets Investment Management LLC raised its position in shares of Regeneron Pharmaceuticals by 86,013.3% in the third quarter. International Assets Investment Management LLC now owns 880,939 shares of the biopharmaceutical company’s stock valued at $926,078,000 after buying an additional 879,916 shares in the last quarter. Charles Schwab Investment Management Inc. increased its position in shares of Regeneron Pharmaceuticals by 1.7% in the third quarter. Charles Schwab Investment Management Inc. now owns 673,261 shares of the biopharmaceutical company’s stock worth $707,759,000 after purchasing an additional 11,499 shares during the period. Massachusetts Financial Services Co. MA lifted its position in Regeneron Pharmaceuticals by 12.4% during the second quarter. Massachusetts Financial Services Co. MA now owns 540,293 shares of the biopharmaceutical company’s stock worth $567,864,000 after purchasing an additional 59,769 shares during the period. BNP PARIBAS ASSET MANAGEMENT Holding S.A. grew its stake in Regeneron Pharmaceuticals by 23.8% during the second quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. now owns 500,274 shares of the biopharmaceutical company’s stock worth $525,804,000 after buying an additional 96,266 shares in the last quarter. Finally, TD Asset Management Inc raised its position in shares of Regeneron Pharmaceuticals by 30.4% in the 2nd quarter. TD Asset Management Inc now owns 351,545 shares of the biopharmaceutical company’s stock valued at $369,484,000 after buying an additional 82,034 shares in the last quarter. 83.31% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several equities research analysts have weighed in on REGN shares. Oppenheimer cut their target price on Regeneron Pharmaceuticals from $1,150.00 to $1,000.00 and set an “outperform” rating for the company in a research note on Wednesday, November 6th. Guggenheim lifted their target price on Regeneron Pharmaceuticals from $1,180.00 to $1,300.00 and gave the company a “buy” rating in a research report on Friday, August 2nd. Piper Sandler dropped their target price on shares of Regeneron Pharmaceuticals from $1,242.00 to $1,195.00 and set an “overweight” rating for the company in a report on Friday, November 1st. Morgan Stanley cut their target price on shares of Regeneron Pharmaceuticals from $1,235.00 to $1,184.00 and set an “overweight” rating on the stock in a research report on Friday, November 1st. Finally, Wolfe Research began coverage on shares of Regeneron Pharmaceuticals in a report on Friday, November 15th. They set an “outperform” rating and a $1,150.00 price target for the company. One investment analyst has rated the stock with a sell rating, four have given a hold rating, eighteen have assigned a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $1,099.55.

Regeneron Pharmaceuticals Trading Up 0.5 %

REGN opened at $753.03 on Wednesday. The company has a market cap of $82.75 billion, a P/E ratio of 18.63, a price-to-earnings-growth ratio of 2.89 and a beta of 0.15. The company has a fifty day moving average price of $929.13 and a two-hundred day moving average price of $1,024.43. The company has a current ratio of 5.28, a quick ratio of 4.46 and a debt-to-equity ratio of 0.09. Regeneron Pharmaceuticals, Inc. has a 1-year low of $735.95 and a 1-year high of $1,211.20.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.